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A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthAbstract
PPARligands evoke a profound mitogenic response in rodent liver, and the aim of this study 
was to characterise the kinetics of induction of DNA synthesis. The CAR ligand, 1,4-bis[2-(3,5-
dichoropyridyloxy)]benzene, caused induction of hepatocyte DNA synthesis within 48 hours in 
129S4/SvJae mice, but the potent PPAR ligand, ciprofibrate, induced hepatocyte DNA syn-
thesis only after 3 or 4 days dosing; higher or lower doses did not hasten the DNA synthesis 
response. This contrasted with the rapid induction (24 hours) reported by Styles et al. (Carcino-
genesis 9:1647-1655). C57BL/6 and DBA/2J mice showed significant induction of DNA syn-
thesis after 4, but not 2, days ciprofibrate treatment. Alderley Park and 129S4/SvJae mice dosed 
with methylclofenapate induced hepatocyte DNA synthesis at 4, but not 2, days after dosing, 
and proved that inconsistency with prior work was not due to a difference in mouse strain or 
PPARligand. Ciprofibrate-induced liver DNA synthesis and growth was absent in PPAR-
null mice, and are PPAR-dependent. In the Fisher344 rat, hepatocyte DNA synthesis was in-
duced at 24 hours after dosing, with a second peak at 48 hours. Lobular localisation of hepato-
cyte DNA synthesis showed preferential periportal induction of DNA synthesis in rat, but 
panlobular zonation of hepatocyte DNA synthesis in mouse. These results characterise a mark-
edly later hepatic induction of panlobular DNA synthesis by PPAR ligands in mouse, com-
pared to rapid induction of periportal DNA synthesis in rat.
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A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthIntroduction
The peroxisome proliferators were originally characterised as a class of structurally diverse 
compounds that caused liver cancer in rodents {Reddy, 1980 #81}, and induced substantial 
changes in liver ultrastructure, including proliferation of endoplasmic reticulum and peroxi-
somes. This class of agents is now known to act through activation of the Peroxisome Prolifer-
ator-Activated Receptor  (PPAR) {Issemann, 1990 #70}, and it is clear that this class of 
carcinogen has a non-genotoxic mode of action {Ashby, 1994 #55; Peters, 1997 #40}. The po-
tent carcinogenicity of this class is shown by the fact that Wy-14,643 can induce 100% multi-
focal liver cancer in rodents after one year {Cattley, 1991 #68}. Ciprofibrate and 
methylclofenapate are potent PPAR ligands {Mukherjee, 2002 #219} that are also potent 
hepatocarcinogens {Meyer, 2003 #235; Tucker, 1995 #241}.
The mechanism whereby PPAR ligands cause cancer is still largely unclear {Ashby, 1994 
#55; Klaunig, 2003 #242; Peters, 2005 #243}. It is clear that DNA synthesis plays an important 
role in carcinogenesis, and peroxisome proliferators induce hepatic DNA synthesis which is re-
lated to carcinogenesis {Marsman, 1988 #77}. It is therefore desirable to understand the mech-
anisms controlling the induction of DNA synthesis by ligands of the PPAR, particularly since 
these ligands augment normal liver size, in contrast to the regenerative growth pathways in-
duced by partial hepatectomy {Mangnall, 2003 #245}. The mechanisms underlying PPAR lig-
and-induced augmentative liver growth are poorly understood {Menegazzi, 1997 #124; Peters, 
2005 #243}, beyond noting that DNA synthesis is dependent upon the PPAR{Peters, 1997 
#40}.
The availability of mouse genetic tools {Ledda-Columbano, 2002 #112; Lee, 1995 #53} com-
bined with the potent liver growth effect of PPAR ligands in the mouse {Peters, 1997 #40}, 
provides a compelling reason for using the mouse to characterise the kinetics and mechanisms 
of induction of hepatocyte DNA synthesis. It is important to characterise the kinetics of induc-
tion of DNA synthesis by PPAR ligands in the mouse, as this information is essential for un-
derstanding the relationship with genes that regulate the induction of DNA synthesis. The early 
kinetics of induction of DNA synthesis by PPAR ligands were characterised using flow cy-
tometry to characterise DNA synthesis in rodent liver {Styles, 1987 #80}. Methylclofenapate 
(MCP) induced high levels of DNA synthesis by as early as 24 hours after dosing in the Alderley 
Park (AP) mouse {Styles, 1988 #78}, and the kinetics of induction were confirmed by another 
study in C57BL/6 mice {Styles, 1990 #73}. However, there is one report using immunohisto-21/2/09 Page 3
A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthchemical detection of BromodeoxyUridine (BrdU) incorporation in the CD-1 mouse that shows 
induction of DNA synthesis only after three/ four days of dosing with the potent PPAR ligand, 
ciprofibrate, {Ledda-Columbano, 2003 #88}, and so this area is in dispute.
Characterisation of the kinetics of induction of DNA synthesis is crucial for understanding the 
relationship with induced genes that might regulate this response, and so we have examined the 
time course of induction of hepatocyte DNA synthesis by PPAR ligands in several mouse 
strains, and in the rat. In contrast to previous reports, we show that there are species-specific 
kinetics of induction of DNA synthesis, and that the zonation of PPAR ligand-induced DNA 
synthesis is different between mouse and rat.21/2/09 Page 4
A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthMaterials And Methods
All the chemicals were of the highest quality available. Ciprofibrate was a kind gift of Sanofi-
Aventis, and methylclofenapate (MCP), a kind gift of Dr C R Elcombe (CXR Biosciences, Dun-
dee) was synthesised by Lancaster synthesis Ltd, Morecambe, Lancs, UK. TCPOBOP was ob-
tained from Sigma (Poole, UK). 129S4/SvJae mice, and their PPAR null congenic strain 
(129S4/Jae-Pparatm1Gonz/tm1Gonz) {Lee, 1995 #53} were a kind gift of Frank Gonzalez (NIH, 
MD, USA), and were maintained as a colony in house. C57BL/6J:CRL and DBA/2J mice were 
obtained from Charles River Laboratories, Alderley Park (AP) mice from AstraZeneca Pharma-
ceuticals, and male Fischer 344 rats (F344/NHsd) were purchased from Harlan UK Ltd (Bices-
ter, UK).
Chronic treatment protocol.  Mice (8-9 weeks old) or rats (14-15 weeks old) were randomised 
to treatment groups (normally n=6), then acclimatised to 10% orange juice in tap water as their 
sole source of drinking water for one week. Bromodeoxyuridine (BrdU) was then added to the 
10% orange juice (0.8 mg ml-1 final concentration), and after one day of exposure to the BrdU, 
animals were dosed by gavage with xenobiotic in corn oil (20 ml kg-1 bodyweight), then dosed 
as indicated until killed by pentobarbital overdose. Body weight was determined daily through-
out the procedure.
Acute rat treatment protocol. Rats (14-15 weeks old) were randomised to treatment group, 
then dosed with peroxisome proliferator (in corn oil, 20 ml kg-1 bodyweight) by gavage. At the 
indicated time after treatment, animals were dosed i.p. with 100 mg kg-1 bodyweight of BrdU 
in sterile phosphate-buffered saline. Animals were killed by i.p. pentobarbital overdose 2 hours 
after BrdU administration.
Immunohistochemistry. A blood sample was taken at necropsy, and serum prepared, followed 
by storage at -80°C until determination of alanine aminotransferase activity (ALT). The liver 
was weighed, and a section of left lobe and small intestine were fixed in 10% neutral buffered 
formalin overnight at room temperature. Fixed tissues were used to prepare blocks, then heat 
induced epitope retrieval used with the Amersham mouse anti-BrdU labelling system to visual-
ise BrdU; the specific nuclear staining required both primary and secondary antibodies, and ad-
ministration of BrdU (data not shown). Slides were counterstained with Harris’ haemotoxylin, 
then mounted with distyrene, plasticiser and xylene. For each animal, 2000 hepatocyte nuclei 
were scored in random fields, and the labelling index is (BrdU labelled hepatocyte nuclei/ total 
hepatocyte nuclei)*100. Hepatocytes were identified morphologically. A sample of small intes-21/2/09 Page 5
A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthtine from each animal was tested as a positive control. For the determination of zonal distribu-
tion of labelled hepatocytes, the method was essentially as described {Barrass, 1993 #92}. 
Briefly, a field was defined as a radius of five to seven cells around either the portal space (the 
periportal region) or the central vein (the perivenous region), using small vessels of similar size. 
Five fields were counted for each of the periportal and centrilobular zones for each animal, and 
the total number of labelled nuclei was recorded.
Statistics. Students t-test was used for comparison of two groups, and a paired t-test for exam-
ining body weight loss. ANOVA followed by a post-hoc test (Dunnett’s, Newman-Keuls) was 
used for multiple comparisons. For time-course studies, the control group timepoints were test-
ed to determine if they were significantly different from each other. If not, the control group val-
ues were pooled, and the pooled values used for comparisons against the treated groups 
(Fig. 2A, C, Fig. 3, Fig. 4, Fig. 5A).21/2/09 Page 6
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Experiments were undertaken to determine whether PPARligands induce hepatic DNA syn-
thesis in mice at 24 hours after dosing {Styles, 1990 #73; Styles, 1988 #78}. Male 129S4/SvJae 
mice were administered the potent PPAR ligand, ciprofibrate, and hepatocytes labelled with 
BrdU, essentially as described for the rat acute dosing protocol (Materials and Methods), except 
with i.p. administration of ciprofibrate. This protocol yielded satisfactory staining of intestinal 
nuclei for BrdU as a positive control for labelling, but showed no significant induction of hepa-
tocyte DNA synthesis over 18-42 hours, over a dose range of 25-100 mg ciprofibrate kg-1 bod-
yweight (unpublished data). Administration of BrdU at 2 hours before death limits the window 
for detection of DNA synthesis to two hours, and so BrdU was administered continuously in the 
drinking water to ensure that there was continuous exposure to BrdU. Continuous exposure to 
BrdU is known to be more sensitive for detecting low levels of DNA synthesis, or where DNA 
synthesis occurs over a period of days {Eldridge, 1990 #226}. Although BrdU has been admin-
istered in the drinking water at doses of 1 mg ml-1, e.g. {Ledda-Columbano, 2003 #88}, admin-
istration of BrdU at 0.8 mg ml-1 in the drinking water led to significant body weight loss in Balb/
c or 129S4/SvJae mice (data not shown); several studies show body weight loss with BrdU in 
the drinking water {Reome, 2000 #238; Jecker, 1997 #240}, attributed to the bitter taste of the 
BrdU. Therefore, 129S4/SvJae mice were acclimatised to 10% orange juice as the sole source 
of drinking water for one week, before adding the BrdU  (0.8 mg ml-1) to the 10% orange juice; 
the hypothesis was that the orange juice would mask the taste of the BrdU. This protocol yields 
stable mouse body weights (Fig. 1A), and effective labelling of a positive control tissue, the 
small intestine (Supplementary Figure 1): note that the nuclear labelling of intestinal cells is uni-
form throughout the length of villus stained, showing that there is consistent BrdU-staining, and 
suggesting consistent bioavailability of BrdU, throughout the period of dosing with BrdU. A 
single dose of 100-400 mg kg-1 ciprofibrate did not increase serum ALT levels, demonstrating 
that these doses of ciprofibrate did not cause hepatotoxicity, and regenerative regrowth in the 
liver (Fig. 1A). These doses did increase liver weight at 48 hours after dosing, which was sta-
tistically significant (Fig. 1A), but failed to cause a statistically significant increase in labelling 
of hepatocyte labelling index (Fig. 1A).
In order to verify that the chronic BrdU labelling protocol leads to efficient incorporation of 
BrdU label in liver, as well as intestine, animals were treated with the CAR agonist, 1,4-bis[2-
(3,5-dichoropyridyloxy)]benzene (TCPOBOP), at 3 mg kg-1, which is characterised to cause 21/2/09 Page 7
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statistically significant three-fold increase in ALT in male, but not female, mice (data not 
shown), showing a small effect on liver cell damage. The liver to body weight ratio was signif-
icantly increased in both male and female mice (Fig. 1B), and the hepatocyte labelling index 
was induced by TCPOBOP treatment to 25-50% (Fig. 1B,C,D). Thus the BrdU dosing method-
ology leads to effective labelling of hepatocyte DNA synthesis that has been induced within 48 
hours of xenobiotic (TCPOBOP) treatment in 129S4/SvJae mice; consequently an artefact of 
dosing methodology can be excluded as a reason for the failure to detect induction of hepatic 
DNA synthesis in mouse by PPAR ligands (Fig. 1).
The time course of the hepatic response to ciprofibrate was examined, to determine if the DNA 
synthesis response occurs at a later stage than in the first two days after dosing. Fig. 2 shows 
that liver weight is significantly increased as early as 2 days after dosing, and that liver weight 
has increased by ~100% at 6 days after dosing commenced. The DNA synthesis response was 
later than the liver growth, with significant induction after three days of administration of cip-
rofibrate (although with large variation) and subsequently (Fig. 2A). In order to ensure that the 
kinetics of induction of DNA synthesis was not an artefact of too high or low a dose, the hepa-
tocyte DNA synthesis response was examined after three or four days of dosing with ciprofi-
brate (Fig. 2B). As little as 10 mg kg-1 day-1 of ciprofibrate caused a significant increase in liver 
to body weight ratio, and there was a tendency for the increase in weight to be larger after four 
days, compared to three days (Fig. 2B). In this experiment, the induction of DNA synthesis was 
lower at three days than in the previous experiment (Fig. 2A,B), but the induction of DNA syn-
thesis was statistically signficant. At four days after dosing, there was a robust induction of 
hepatocyte DNA synthesis at 30, or 100 mg kg-1 day-1 of ciprofibrate (Fig. 2B), and this latter 
dose was demonstrated to give the highest induction of DNA synthesis. The hepatic effects of 
ciprofibrate were examined in female mice to determine if there was a sex difference in re-
sponse. The liver to body weight ratio was significantly induced after three or four days of dos-
ing (Fig. 2C), but hepatocyte DNA synthesis was only significantly increased after four (but not 
three) days of dosing (Fig. 2C), comparable with the male, showing that there is no marked sex 
difference in induction of hepatocyte DNA synthesis by PPAR ligands. Thus ciprofibrate in-
duced hepatocyte DNA synthesis only after three/ four days of dosing, and the dose giving the 
highest induction of DNA synthesis has been defined.21/2/09 Page 8
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the fact that the response seen in (Fig. 2) is much later than that reported by Styles {Styles, 1988 
#78; Styles, 1990 #73}. Therefore, we investigated the induction of hepatocyte DNA synthesis 
in C57BL/6J mice; however the results are essentially similar to those seen in 129S4/SvJae 
mice, with significant induction of hepatocyte DNA synthesis after four (but not two) days of 
dosing with ciprofibrate (Fig. 3A). DBA/2J mice were also dosed using a similar protocol 
(Fig. 3B); liver: body weight ratio is significantly induced at two days after dosing, but the he-
patic labelling index is not significantly increased at two days after dosing, but is significantly 
increased at four and six days after dosing commenced. It is therefore less likely that the dis-
crepancy between this study, and the work of Styles {Styles, 1988 #78; Styles, 1990 #73}, is 
simply due to an idiosyncracy of the 129S4/SvJae mouse strain, since these workers had shown 
that methylclofenapate induces hepatocyte DNA synthesis by 24 hours in C57BL/6 mice 
{Styles, 1990 #73}. In order to exclude the possibility that ciprofibrate may have some effect 
that is not mediated by the PPAR, the effects of ciprofibrate were tested in congenic 129S4/
SvJae mice which are nullizygous for the PPAR (unpublished data). These data showed that 
ciprofibrate at 100 mg kg-1 day-1 had no significant effect on liver to body weight ratio, nor on 
the hepatocyte labelling index, or ALT (data not shown), consistent with the work of Peters et 
al. {Peters, 1997 #40}. This proves that the induction of liver growth and hepatic DNA synthesis 
by ciprofibrate requires PPAR, and given that ciprofibrate is a known PPAR ligand and per-
oxisome proliferator{Meyer, 2003 #235; Mukherjee, 2002 #219}, this constitutes proof that 
these effects are caused by a direct action of ciprofibrate on the PPAR.
Styles showed rapid induction of hepatic DNA synthesis in Alderley Park (AP) mice, using 
MCP, and given the importance of this report, we undertook a direct comparison between 
129S4/SvJae and AP mice using the same dose of the same peroxisome proliferator (MCP) used 
by Styles {Styles, 1988 #78}. MCP caused a significant induction of liver growth at days two 
to four after dosing commenced (Fig. 4A) in 129S4/SvJae mice, and showed significant induc-
tion of hepatocyte DNA synthesis after three or four (but not two) days of dosing (Fig. 4A); this 
is consistent with previous data using the PPAR ligand, ciprofibrate (Fig. 1-Fig. 3). When this 
experiment was repeated using AP mice, similar results were obtained (Fig. 4B): hepatic growth 
was statistically significant after 2-4 days of dosing, but labelling index was not significantly 
increased after one, two or three days dosing, and was only statistically significantly increased 
after four days of dosing with MCP. These data exclude mouse strain or peroxisome proliferator 
as a cause of the delayed hepatic DNA synthesis response seen with our data, as compared to 21/2/09 Page 9
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induction of hepatic DNA synthesis by PPAR ligands is delayed until after three/ four days in 
the mouse.
A direct comparison was made with the induction of hepatic DNA synthesis by ciprofibrate in 
the Fisher 344 rat. Hepatocyte DNA synthesis was significantly increased at 24, 48 and 96 hours 
after dosing when using the chronic BrdU dosing protocol, attaining a 38% labelling index  
(Fig. 5A). The labelling index  at the 24 hour time point was significantly different from control 
(control 1.33 ± 0.37% (mean and SD) versus ciprofibrate 4.4 ± 2.3%) on a t-test. Chronic dosing 
with BrdU involves exposing animals to the labelling agent for a period of days, thereby leading 
to a high background value for DNA synthesis in the control group as a result of DNA synthesis 
over the whole of this period. Therefore, the experiment was repeated using an acute i.p. dose 
of BrdU at two hours before killing the animals, to characterise the DNA synthesis response 
within the shorter time frame of the first 48 hours after dosing. The liver weight was slightly, 
but significantly, increased at 30 and 36 hours after dosing, with a larger increase at 48 hours 
after dosing with ciprofibrate (Fig. 5A). In contrast to the mouse (Fig. 1-Fig. 4), ciprofibrate 
significantly induced hepatocyte DNA synthesis as early as 24 hours after dosing, with levels 
falling back to background before a second wave of DNA synthesis at 48 hours after the first 
dose (Fig. 5B). The induction of hepatocyte DNA synthesis at 24 hours was examined by var-
ying the dose of ciprofibrate, confirming an early induction of hepatocyte DNA synthesis at 24 
hours, and further showing that 50-200 mg ciprofibrate kg-1 bodyweight are optimal doses for 
inducing hepatocyte DNA synthesis (Fig. 5C). At 300 mg ciprofibrate kg-1 bodyweight, there 
is no significant induction of liver to bodyweight ratio, and no induction of hepatocyte DNA 
synthesis; the diminished nature of these responses, compared with lower doses, suggests that 
300 mg kg-1 bodyweight is overtly toxic and is suppressing the liver growth response. These 
results demonstrate that there is a species difference between mouse and rat in the kinetics of 
induction of hepatocyte DNA synthesis by PPAR ligands.
Given these distinct results in mouse and rat, the lobular zonation of induction of hepatocyte 
DNA synthesis in liver was examined, as previously described {Barrass, 1993 #92}. Fig. 6A 
shows that there is marked periportal distribution of labelled hepatocyte nuclei in the rat, where-
as the mouse shows a pan-lobular distribution of labelled cells. Quantification of these data 
(Fig. 6B) shows that there is a difference in the zonation of induced hepatocyte DNA synthesis 
between the rat and mouse, with statistically significant preferential periportal induction of 21/2/09 Page 10
A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthDNA synthesis by PPAR ligands in the Fisher344 rat, and no significant difference between 
periportal and centrilobular induction of DNA synthesis in the 129S4/SvJae mouse. The data in 
Fig. 6B are typical of data from 129S4/SvJae mice treated with 30-100 mg ciprofibrate kg-1 day-
1 for three or four days, 100 mg ciprofibrate kg-1 day-1 for three to 6 days, 25 mg kg-1 day-1 
methylclofenapate for three or four days, or C57BL/6 mice treated with 100 mg ciprofibrate kg-
1 day-1 for four days (Data not shown). Likewise, the preferential periportal distribution of in-
duced DNA synthesis in rat hepatocytes is consistent over a dose range of 50-200 mg ciprofi-
brate kg-1, and when using a chronic BrdU administration regime (data not shown).21/2/09 Page 11
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The mouse and rat show differential kinetics of induction of hepatocyte DNA synthesis after 
exposure to PPAR ligands, with the mouse response being delayed to three days after dosing. 
Given that these results differ from previous work {Styles, 1988 #78; Styles, 1990 #73}, it was 
necessary to to undertake extensive controls. Immunohistochemical detection of incorporated 
BrdU has been extensively validated for detection of replicating hepatocytes (e.g. {Eldridge, 
1990 #226; Ledda-Columbano, 2003 #88}), and positive controls include labelling of intestine, 
labelling in liver from mice treated with the CAR ligand, TCPOBOP and that results obtained 
using acute and chronic BrdU-dosing protocols were comparable. Hence the labelling regime 
and immunohistochemical detection system were robustly validated for detecting early induc-
tion of DNA synthesis. BrdU treatment can decrease body weight (unpublished data), and so 
mouse body weight was measured, although this elementary control is not often described in the 
literature; mouse body weight was found to be unaffected by BrdU in all experiments shown. 
PPAR ligands can cause (focal) necrosis (e.g. {Woods, 2007 #212}), thereby leading to regen-
erative growth; therefore serum ALT (a marker of liver cell damage) was shown to be unaffect-
ed by the doses of PPAR ligands used in this study, and there was no evidence of necrosis 
detected by examination of histological sections (not shown). These control experiments prove 
unambiguously that ciprofibrate fails to induce hepatocyte DNA synthesis within two days after 
dosing.
Styles found rapid induction of hepatocyte DNA synthesis by PPAR ligands in  Alderley Park 
(AP) {Styles, 1988 #78} and heterozygous Snell dwarf mice on C57BL/6 {Styles, 1990 #73}, 
whereas our results were obtained in 129S4/SvJae mice, suggesting a strain difference in re-
sponse. Mouse strain can affect liver function {Akiyama, 2001 #221; Manenti, 1994 #223}, but 
published evidence that strain differences affect peroxisome proliferation is inconclusive 
{Budroe, 1992 #63; Dwivedi, 1989 #250; Jones, 1995 #50}. C57BL/6 and DBA/2J mice were 
treated with ciprofibrate, showing that the kinetics of induction of liver growth and DNA syn-
thesis were similar to that in 129S4/SvJae mice. AP mice are an outbred stock of Swiss origin 
{Beck, 2000 #224; Chia, 2005 #225}, and so we directly tested in AP mice using the same dose 
of the same PPAR ligand described in {Styles, 1988 #78}. The induction of hepatocyte DNA 
synthesis response was delayed to three/ four days after administration of MCP in 129S4/SvJae 
and in AP mice, thus showing remarkably little effect of strain difference in the response of the 
mouse to PPAR ligands in three different mouse strains. Thus, we have been unable to repli-21/2/09 Page 12
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bred, may have undergone strain drift, the C57BL/6 mice are inbred, and are unlikely to show 
significant strain drift. Moreover, the concordance between the results obtained in 129S4/SvJae, 
AP, C57BL/6J and DBA/2J mice in our hands excludes the possibility that the discordance be-
tween our data, and those of Styles {Styles, 1988 #78; Styles, 1990 #73}, arises from mouse 
strain differences.
The possibility that ciprofibrate had off-target (i.e. non-PPAR mediated) effects that con-
founded its liver growth function was also considered. Ciprofibrate is a potent PPAR ligand 
{Mukherjee, 2002 #219}, has similar effects to another potent {Bell, 1991 #67; Bell, 1991 #65} 
PPARligand, MCP, and the use of PPAR-nullizygous mice provides compelling evidence 
that the liver growth and DNA synthesis effects of ciprofibrate are mediated by the PPAR.
It is difficult to explain the difference in kinetics of induction of DNA synthesis reported by 
Styles {Styles, 1988 #78; Styles, 1990 #73}, and in this study. Table 1 compares the meth-
odolgy used by Styles et al and in this paper, and the principal remaining variable is that this 
study used immunohistochemical detection of incorporated BrdU, whereas Styles detected in-
corporated BrdU by isolation of hepatocytes, and flow cytometry of the isolated hepatocytes 
{Styles, 1987 #80}. PPAR ligands cause an increase in liver size, and the consequent increase 
in hepatocyte size (unpublished data) could cause differential recovery of liver cells during the 
hepatocyte isolation procedure between control and treated animals, or alternatively may differ-
entially affect the propidium iodide staining. There are no controls to determine whether this is 
so; and both of these issues could introduce artefactual error into the determination of the pro-
portion of labelled hepatocytes by flow cytometry. Miller et al. were unable to replicate the re-
sults of Styles on rat hepatocyte ploidy {Miller, 1996 #46; Styles, 1987 #80}, which shows 
difficulty in reproducing results obtained by the flow cytometry methodology. The reason for 
the difference in results remains obscure, but we have excluded the choice of PPAR ligand, 
dose, sex and strain differences as possible variables. Further, our results are consistent with 
other reports {Ledda-Columbano, 2003 #88}, and so we conclude that the induction of hepato-
cyte DNA synthesis is delayed until three days after administration of PPAR ligand, and we 
propose that the results obtained by Styles are an artefact arising from the cell isolation and flow 
cytometric analysis of liver cells.21/2/09 Page 13
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duction of DNA synthesis in the rat. Our results in the rat are consistent with our previous dem-
onstration that PPAR ligands cause rapid (ca. 24 hours) induction of DNA synthesis in rat 
hepatocytes in vitro {Plant, 1998 #35; Plant, 1998 #39}, and the finding that the PPAR lig-
ands, nafenopin and Wyeth-14,643, causes induction of hepatic DNA synthesis at 24 hours after 
dosing in Wistar and Fisher344 rats, respectively {Menegazzi, 1997 #124; Miller, 1996 #46}. 
However, it is essential to use the same methodology in the same laboratory to obtain a reliable 
comparison of mouse and rat. This delayed response of the mouse to induction of hepatocyte 
DNA synthesis is reminiscent of the response to partial hepatectomy, where mouse hepatocyte 
DNA synthesis commences 12-16 hours later than in the rat; after partial hepatectomy, it has 
been shown that the faster response of the rat hepatocyte is cell autonomous {Weglarz, 2000 
#229}. However, the delayed induction of DNA synthesis in mouse does not reflect an intrinsic 
lack of capability in the mouse hepatocyte, as TCPOBOP triggers a fast DNA synthesis re-
sponse, signalling via the CAR receptor. Thus the kinetics of induction of hepatocyte DNA syn-
thesis are specific to the signalling pathway initiating DNA synthesis. The delayed induction of 
DNA synthesis response in mouse by PPAR ligands is unlikely to be due to a species differ-
ence in the amount of the PPAR, since the receptor is present at high levels in mouse, com-
pared to other rodents {Bell, 1998 #36; Choudhury, 2000 #31; Choudhury, 2004 #12}.
The distinct species-specific kinetics of induction of hepatocyte DNA synthesis is associated 
with altered zonation of induced DNA synthesis, where the rat shows preferential induction of 
DNA synthesis in the periportal region, and the mouse shows pan-lobular induction of DNA 
synthesis. The zonation of induction of enzymes by various xenobiotics has been extensively 
demonstrated {Bars, 1992 #64; Oinonen, 1994 #232}, but the zonal induction of DNA synthesis 
is much less well characterised, although reliable methods have been established {Barrass, 1993 
#92}. Our results confirm and extend the findings of Barrass et al., by showing that a distinct 
PPAR ligand, ciprofibrate, also induces zonal induction of hepatocyte DNA synthesis in rat, 
and by showing that DNA synthesis does not show zonal distribution in several mouse strains. 
The periportal distribution of induced hepatocyte DNA synthesis in rat is distinct from the pref-
erentially centrilobular induction of cytochrome P450 and peroxisomal enzymes induced by 
PPAR-ligands {Bars, 1993 #60; Bell, 1991 #67}, yet the induction of both DNA synthesis and 
enzymes are PPAR-dependent. This suggests that PPAR-independent mechanism must be 
responsible for the distinct zonation of DNA synthesis and peroxisomal enzymes. Characterisa-
tion of the zonal distribution of the PPAR- associated coactivators, or microRNAs that are 21/2/09 Page 14
A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthknown to be required for induction of DNA synthesis {Matsumoto, 2007 #3}{Shah, 2007 #2}, 
are obvious candidates for mediating these PPAR-independent effects. While it is known that 
Apc is the “zonation-keeper” in mouse liver {Benhamouche, 2006 #251}, it is not clear that ex-
actly the same pathway applies in rat liver. Given the complex web of interactions between Apc 
and -catenin, and that -catenin signalling regulates liver growth pathways {Tan, 2006 #252}, 
it can be hypothesised that species differences in regulation of the -catenin signalling pathway 
mediate PPAR-ligand induced hyperplasia and lobular localisation. Given the availability of 
liver-specific knockouts of -catenin {Tan, 2006 #252}, this hypothesis is partly experimentally 
tractable.
The definition of the rapid induction of hepatocyte DNA synthesis in rat by PPAR ligands 
opens up opportunities for investigating the mechanism of induction of the growth response, by 
relating the early gene induction events to subsequent hyperplasia. There is evidence that the 
liver growth programme induced by PPAR ligands is quite distinct from that seen during re-
generation or after treatment with growth factors e.g. {Menegazzi, 1997 #124; Plant, 1998 #35; 
Plant, 1998 #39}: the PPAR-ligand induced growth defined in this paper offers a tractable sys-
tem for investigating how augmentative liver growth is regulated.21/2/09 Page 15
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FIG. 1. Ciprofibrate does not induce hepatic DNA synthesis within 48 hours in mice. A, 
Groups of six male 129S4/SvJae mice (8-9 weeks old) were acclimatised to 10% orange juice 
as sole source of drinking water for one week, then BrdU added to the orange juice at a final 
concentration of 0.08%(w/v). After one day on BrdU, animals were dosed by gavage with corn 
oil vehicle (Control), or the indicated dose of ciprofibrate; animals were killed two days after 
dosing with ciprofibrate. The top left panel shows relative bodyweight of animals in each group 
(each animal is normalised to day 0, which is set at 1). Results are shown as mean ± Standard 
Deviation. The period where BrdU was administered is shown by a horizontal line, labelled “Br-
dU”, and the time of administration of ciprofibrate by a vertical arrow labelled “Ciprofibrate”. 
Body weight was tested with a paired t-test, and there were no significant differences from the 
time of initial treatment with BrdU. The top right panel shows serum ALT in this experiment; 
there are no significant differences. Bottom left panel shows the liver-to-bodyweight ratio is 
shown as a percentage; values marked with a * are significantly different at P<0.05 (Dunnett’s 
multiple comparison test). The bottom right panel shows labelling indices determined for liver 
sections; all animals were shown to have labelling in intestinal samples (data not shown). There 
were no significant differences from control at P<0.05. B, groups of male or female mice were 
treated (as in A), but with a single gavage dose of 3 mg of TCPOBOP kg-1 of bodyweight, dis-
solved in corn oil. The left panel shows body weight, and the right panel shows hepatocyte la-
belling index. An asterisk denotes P<0.05 (t-test versus control). There was no effect on body 
weight in this experiment, but TCPOBOP caused a statistically-significant three-fold increase 
in serum ALT in male (but not female) mice (not shown). C and D, show typical liver sections 
labelled with an anti-BrdU antibody (black nuclei) and counterstained with haemotoxylin, for 
male control and TCPOBOP-treated animals, respectively. The scale bar is 50 m.
FIG. 2. Kinetics of hepatic response to ciprofibrate in male and female mice. A, Groups 
of male 129S4/SvJae mice were treated with BrdU, as described in A, and ciprofibrate at 100 
mg kg-1 day-1, with the exception that animals were killed at 2-6 days after starting dosing with 
ciprofibrate. There was no significant effect on relative bodyweight, or serum ALT (Data not 
shown). The left panel shows the liver to bodyweight ratio, and the right panel shows the hepa-
tocyte labelling index; graphs show the number of days after dosing with corn oil/ ciprofibrate 
on the X-axis. B, Groups of male 129S4/SvJae mice were dosed with the indicated daily dose 
of ciprofibrate or vehicle control, and killed after three or four days (the three and four day ex-21/2/09 Page 18
A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthperiments were not contemporaneous), essentially as described in A. There was no significant 
effect on relative bodyweight, or serum ALT (Data not shown). The left panel shows the liver 
to bodyweight ratio, and the right panel shows the hepatocyte labelling index. C, groups of fe-
male 129S4/SvJae mice were treated daily with 100 mg kg-1 ciprofibrate or vehicle, as in panel 
B. There was no significant effect on relative bodyweight, or serum ALT (Data not shown). 
FIG. 3. Effect of strain and PPAR on hepatic response to ciprofibrate. A, Groups of six 
C57BL/6J mice were dosed with 100 mg kg-1 day-1 ciprofibrate, or vehicle control, essentially 
as described for Fig. 2, and killed on days 2 and 4. The left panel shows liver to body weight 
ratio, and the right panel shows hepatocyte labelling index. B, Groups of six DBA/2J mice were 
dosed with with ciprofibrate as for A above, and killed on days 2, 4 and 6. The left panel shows 
liver to body weight ratio, and the right panel shows hepatocyte labelling index. Statistically-
significant difference from the control group is indicated by an asterisk (P<0.05).
FIG. 4. Hepatic response to methylclofenapate in 129 and AP mice. A, Groups of six 
129S4/SvJae mice were dosed with 25 mg kg-1 day-1 methylclofenapate essentially as de-
scribed for Fig. 2. The left panel shows liver to body weight ratio, and the right panel shows 
hepatocyte labelling index, where * =P<0.05 (Dunnett’s multiple comparison test). B, As for A, 
but using Alderley Park (AP) mice.
FIG. 5. Ciprofibrate induces hepatic DNA synthesis in F344 rats. A, Groups of six Fisher 
344 rats were acclimatised to 10% orange juice, and then 0.08% BrdU in the 10% orange juice, 
essentially as described for Figure 1. Animals were then dosed with corn oil vehicle or 50 mg 
kg-1 day-1 ciprofibrate, and killed on the indicated day for determination of liver weight and la-
belling index. B, Groups of six Fisher 344 rats were dosed by gavage with 50 mg kg-1 day-1 cip-
rofibrate, or corn oil vehicle, and injected with 100 mg kg-1 BrdU at 2 hours before termination, 
as described in the acute labelling protocol in materials and methods. The left panel shows liver 
to bodyweight ratio at the indicated time, and the right panel shows hepatocyte labelling index. 
*=P<0.05 (Dunnett’s multiple comparison test). C, essentially as described in B, rats were 
dosed with the indicated dose of vehicle or ciprofibrate, dosed with BrdU i.p. at 22 hours, and 
killed after 24 hours. Liver to bodyweight ratio is shown in the left panel, and hepatocyte label-
ling index in the right panel.
FIG. 6. Zonation of ciprofibrate-induced hepatocyte DNA synthesis.A, representative pho-
tomicrographs of ciprofibrate induced mouse (left) or rat (right) liver sections, after staining for 21/2/09 Page 19
A. Al Kholaifi et al. Peroxisome proliferator-induced liver growthBrdU incorporation. B, the left panel shows quantification of zonal distribution of periportal 
(PS) and centrilobular (CV) hepatocyte DNA synthesis in 129S4/SvJae mice treated with 100 
mg kg-1 day-1 ciprofibrate for four or six days. Individual animal values are shown, and the 
mean and Standard Deviation are superimposed as a cross with error bar. There was no signif-
icant difference between periportal and centrilobular DNA synthesis. B, as for A, but with Fish-
er 344 rat after two or four days administration. An asterisk indicates that the periportal values 
are significantly different from the centrilobular values at P<0.05 (t-test).21/2/09 Page 20
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